MRK · News · 20261103N
Acquisitions and Divestitures
Merck & Co., Inc. · 2026-11-03 · Importance 40 · Surprise 42 · In source text
Merck agreed to divest its contract development and manufacturing organization (CDMO) business to Lonza. The reported rationale is to sharpen the focus of Merck’s Life Science business sector and give the CDMO business a platform for its next phase of development. The digest does not disclose the transaction value or an expected closing date.
Key facts
- Merck agreed to divest its CDMO business to Lonza; the transaction is described as sharpening the focus of Merck’s Life Science business sector. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | probable | — | Merck agreed to divest its CDMO business to Lonza; the transaction is described as sharpening the focus of Merck’s Life Science business… |
| cash | positive | probable | — | Merck agreed to divest its CDMO business to Lonza; the transaction is described as sharpening the focus of Merck’s Life Science business… |